Canada
· Delayed Price · Currency is CAD InnoCan Pharma Statistics
Total Valuation
InnoCan Pharma has a market cap or net worth of CAD 68.56 million. The enterprise value is 63.13 million.
| Market Cap | 68.56M |
| Enterprise Value | 63.13M |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
| Earnings Date | Nov 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoCan Pharma has 285.69 million shares outstanding. The number of shares has increased by 7.44% in one year.
| Shares Outstanding | 285.69M |
| Shares Change (YoY) | +7.44% |
| Shares Change (QoQ) | +4.02% |
| Owned by Insiders (%) | 5.47% |
| Owned by Institutions (%) | 0.18% |
| Float | 220.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.93 |
| PB Ratio | 10.20 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.63 |
| EV / Sales | 1.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -21.81 |
Financial Position
The company has a current ratio of 3.22, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.22 |
| Quick Ratio | 2.10 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -56.52% and return on invested capital (ROIC) is -31.38%.
| Return on Equity (ROE) | -56.52% |
| Return on Assets (ROA) | -23.77% |
| Return on Capital (ROIC) | -31.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 3.34 |
| Inventory Turnover | 1.19 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.86% in the last 52 weeks. The beta is 3.01, so InnoCan Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 3.01 |
| 52-Week Price Change | -17.86% |
| 50-Day Moving Average | 0.24 |
| 200-Day Moving Average | 0.28 |
| Relative Strength Index (RSI) | 49.50 |
| Average Volume (20 Days) | 57,819 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCan Pharma had revenue of CAD 33.38 million and -5.94 million in losses. Loss per share was -0.02.
| Revenue | 33.38M |
| Gross Profit | 30.04M |
| Operating Income | -3.80M |
| Pretax Income | -3.00M |
| Net Income | -5.94M |
| EBITDA | -3.75M |
| EBIT | -3.80M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 7.10 million in cash and 5,475 in debt, giving a net cash position of 7.10 million or 0.02 per share.
| Cash & Cash Equivalents | 7.10M |
| Total Debt | 5,475 |
| Net Cash | 7.10M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 8.27M |
| Book Value Per Share | 0.02 |
| Working Capital | 8.11M |
Cash Flow
In the last 12 months, operating cash flow was -2.88 million and capital expenditures -19,161, giving a free cash flow of -2.89 million.
| Operating Cash Flow | -2.88M |
| Capital Expenditures | -19,161 |
| Free Cash Flow | -2.89M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 90.01%, with operating and profit margins of -11.40% and -17.80%.
| Gross Margin | 90.01% |
| Operating Margin | -11.40% |
| Pretax Margin | -9.00% |
| Profit Margin | -17.80% |
| EBITDA Margin | -11.25% |
| EBIT Margin | -11.40% |
| FCF Margin | -8.67% |
Dividends & Yields
InnoCan Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.44% |
| Shareholder Yield | -7.44% |
| Earnings Yield | -9.20% |
| FCF Yield | -4.22% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoCan Pharma has an Altman Z-Score of 10.32.
| Altman Z-Score | 10.32 |
| Piotroski F-Score | n/a |